This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -17.24% and 3.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
by Zacks Equity Research
RxSight (RXST) delivered earnings and revenue surprises of 100% and 8.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -3.57% and 10.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 3.85% and 6.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 0% and 4.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 62.22% and 6.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -11.11% and 0.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -12.50% and 1.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 1.69% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Treace Medical Concepts (TMCI) Q4 Earnings Expected to Decline
by Zacks Equity Research
Treace Medical Concepts (TMCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 13.04% and 2.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 60% and 7.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 0% and 6.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -6.78% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Treace Medical Concepts (TMCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Recent Price Trend in Treace Medical Concepts (TMCI) is Your Friend, Here's Why
by Zacks Equity Research
Treace Medical Concepts (TMCI) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Treace Medical Concepts (TMCI) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Treace Medical Concepts (TMCI) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's What Could Help Treace Medical Concepts (TMCI) Maintain Its Recent Price Strength
by Zacks Equity Research
Treace Medical Concepts (TMCI) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 21.43% and 9.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Treace Medical Concepts (TMCI): Can Its 8.4% Jump Turn into More Strength?
by Zacks Equity Research
Treace Medical Concepts (TMCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -9.52% and 4.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 16.67% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Apollo Endosurgery, Inc. (APEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -23.81% and 7.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Soars 8.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Treace Medical Concepts (TMCI) Moves 8.2% Higher: Will This Strength Last?
by Zacks Equity Research
Treace Medical Concepts (TMCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.